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Barrett Parker Wagner1*, Narendranath Epperla2 and Rafael Medina-Flores3Abstract
Clear cell sarcoma is a rare cancer primarily of tendons, fascia, and aponeuroses that can be difficult to discern from
primary cutaneous malignant melanoma. The two cancers share several histological markers, with most cases of
both cancers staining positively for S-100, HMB-45, and melanin. Primary therapy of both cancers involves wide local
excision, but while systemic therapy has proven benefit for malignant melanoma, it has not been established for
clear cell sarcoma.
We report the case of a 58 year old woman with a large, ulcerated, fungating mass on her left lower leg. Frozen
section of the mass showed a malignant epithelioid and spindle cell tumor confined to the subcutaneous tissue. A
provisional diagnosis of soft-tissue sarcoma was made. Through in-depth study of initial biopsy with immunohisto-
chemistry for S-100, HMB-45, MART-1, and MITF, along with karyotyping and FISH analysis for EWS gene rearrangement,
the diagnosis of amelanotic malignant melanoma was confirmed. The patient then underwent systemic treatment with
ipilimumab upon recurrence with good response.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1989338475107348.
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Primary cutaneous malignant melanoma (MM) is an ag-
gressive cancer of melanocytes that causes 75% of skin
cancer deaths [1]. The presentation can vary greatly, with
many different types. These include the four common
subtypes of lentigo maligna, superficial spreading melan-
oma, acral-lentiginous melanoma, and nodular melanoma,
as well as the rarer desmoplastic melanoma and mucosal
melanoma [2]. The prognosis for a patient with MM de-
pends greatly on the tumor stage.
Primary cutaneous malignant melanoma can be very
similar to, but is distinct from, clear cell sarcoma of ten-
dons and aponeuroses (CCSTA) [3]. CCSTA originates
chiefly from tendons, aponeuroses, and fascia of the* Correspondence: bwagner1@wisc.edu
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stated.extremities; most often beginning in the feet or knees of
young adults [2,4]. The cells of origin are suspected to
be of neural crest origin due to evidence of melanocyte
differentiation in many tumors [5]. Further hindering
discrimination from MM, CSSTA cells sometimes pro-
duce melanin, and have been known to extend into the
subcutis and dermis [4]. It is important to distinguish
these two conditions not only due to the difference in
prognosis but also due to difference in treatment.
Though the primary treatment for both these conditions
is wide-margin resection, systemic therapy is beneficial
for those with advanced or metastatic MM, in contrast
to CCSTA, where there is no established benefit to
chemotherapy.
We present the case of a 58 year old female who posed
a diagnostic challenge, as her lesion was initially consid-
ered to be a soft tissue sarcoma based on gross morph-
ology and imaging findings of the mass. However, after al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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malignant melanoma and responded to systemic therapy.
Case presentation
Patient course
A 58 year old woman presented to the emergency de-
partment with a bleeding mass on the medial aspect of
her lower left leg. Three years prior, she sustained a burn
to that area of her leg resulting in a scar. One year ago,
she sustained minor trauma to that region leading to a
small painless bump that slowly progressed in size. She
noticed bleeding from the mass, which prompted her to
seek medical attention. Upon presentation to the emer-
gency department, the bleeding had stopped.
The patient denied constitutional symptoms of fever,
chills and night sweats or recent weight loss. She had no
numbness, tingling or localized weakness. There was no
history of cancer in the family. The patient was married
and worked as a sales clerk. She was a non-smoker and
did not drink alcohol.
Examination showed a multiloculated and fungating
soft tissue mass measuring 15 cm × 18 cm × 5 cm, with
interspersed areas grossly consistent with necrosis.
Neurologic function was normal distal to the mass with
intact ability to flex and extend both the ankle and toes
painlessly. A 6–8 cm non-fungating, palpable mass was
also noted in the left thigh near the groin. Both masses
were non-tender. In addition, right supraclavicular and
bilateral axillary lymphadenopathy was appreciated.
The mass was suspected to be a soft tissue sarcoma. Sta-
ging abdominal, pelvic, and chest CT was performed and
the patient underwent surgical amputation of the left leg
below the knee, as well as excision of masses in the follow-
ing locations: left groin (16 cm), right supraclavicular
(3 cm), left anterior shoulder (3 cm), right wrist, left mid-
back, right posterior axilla, and right lateral breast. The
patient tolerated the lengthy procedure well. Biopsy of the
mass showed sheets and nests of epithelioid and spindle
tumor cells within the superficial and deep dermis and
subcutis, with the epidermis uninvolved. On permanent
section, tumor cells showed no evidence of melanin pig-
ment on Fontana Masson stain (not shown), but S-100
protein, HMB-45, MART-1, and MITF were all positive in
the tumor (Figure 1), which resulted in a histopathological
diagnosis of malignant melanoma. At the request of the
patient’s oncologist, additional fluorescence-in-situ hybri-
dization (FISH) for Ewing Sarcoma Breakpoint Region
(EWSR) was performed and was negative for a rearrange-
ment. In addition, molecular testing for BRAF exon 15,
was negative for the V600E mutation.
Although the primary site could not be discerned with
certainty, assuming that the leg mass is the primary
tumor yielded a stage of T4bN3M1a. Following discharge,
the patient had monthly follow-ups with orthopedics,plastic surgery, and prosthetics. Six months after the ori-
ginal diagnosis, follow-up PET scan showed small lesions
in the liver, spleen, retro-peritoneal lymph nodes and left
external iliac nodes with increased activity. The patient
began treatment with ipilimumab at that time, and was
responsive to therapy.
Discussion
This patient presented with an unusually large tumor on
the lower leg, which she had allowed to grow for approxi-
mately 1 year. Due to the physical appearance and large
presenting size, the diagnosis of sarcoma was made. The
tumor location near the knee with a biopsy showing an un-
involved epidermis, positive staining with S-100 and HMB-
45, and lack of melanin suggested a possibility of CCSTA.
However, with more in-depth testing, the proper diagnosis
of amelanotic malignant melanoma was confirmed.
Melanoma is the most aggressive of the cutaneous ma-
lignancies, causing more than 9,000 deaths in the past year
in the United States. It is responsible for 80% of deaths
from skin cancer despite accounting for only 4% of all der-
matological cancers [6]. Abnormal growth of melanocytes
in MM is due to activation of the mitogen-activated pro-
tein kinase (MAPK) via various mechanisms such as N-
RAS or BRAF mutations [7]. Diagnosis is typically made
histologically, but recent studies have shown promise for
application of FISH for differentiating between nevi and
several melanoma types [8,9]. The prognosis and tumor
behavior varies according to the stage of the melanoma.
In stage I and II (localized) melanomas, the best survival
predictors are tumor thickness, mitotic rate and ulceration
[10]. The prognosis of stage III melanomas is extremely
variable depending on tumor burden, number of involved
nodes, and ulceration. 5 year survival rates of such pa-
tients can vary from 13 to 69% [11]. Stage IV melanoma
carries a grim prognosis, but those with metastasis to
non-visceral sites and/or the lungs have better 1 year sur-
vival rates than those with metastasis to other visceral or-
gans [11]. Furthermore, recent biomarker research has
shown that high MCM3 expression is a sign of poor prog-
nosis that correlates with reduced RBM3 expression [12].
Clear cell sarcoma is a rare but distinct clinic-pathologic
entity, which predominantly affects tendons and aponeur-
oses of adolescents and young adults. It was first described
in 21 cases in 1965 and given the name clear cell sarcoma
of tendons and aponeuroses [13]. It later also became
known as malignant melanoma of the soft parts, although
this name has fallen out of favor as it has become more
clear that the cells of origin are not melanocytes [3]. The
tumor tends to remain localized, with tumor size being
the primary determinant of prognosis.
For CSSTA, surgical resection with wide local margins is
the primary treatment, resulting in 5 and 10 year survival
rates of 59% and 41% respectively [14]. If margins are close,
Figure 1 Immunostains of tissue biopsy. (A): 10× H&E; the dermis was infiltrated by sheets and nests of tumor cells with eosinophilic
cytoplasm and large nuclei with prominent nucleoli, the epidermis was uninvolved. (B): 20× H&E; higher power of tumor within subcutis shows a
nested tumor architecture, neoplastic cells are somewhat discohesive and have bright eosinophilic cytoplasm. (C): 20× S-100; positive nuclear and
cytoplasmic reactivity in tumor cells for S-100. (D): 20× HMB-45; positive cytoplasmic reactivity. (E): 20× Melan-A; positive cytoplasmic reactivity.
(F): 20× MITF; positive nuclear reactivity.
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established benefit to chemotherapy for CSSTA, but in ag-
gressive cases adjuvant therapy is often used [3]. Primary
treatment of MM is wide-margin surgical resection. Senti-
nel lymph node biopsy is recommended for patients with
lesions larger than 1 mm, as well as those with lesions that
are ulcerated or have high mitotic rate [15,16]. Definitive
diagnosis from the nodes is made with fixation and staining
with hemotoxylin and eosin, along with immunohisto-
chemical stains such as S-100, MART-1, and HMB-45 [17].
In contrast to CSSTA, systemic therapy has proven benefit
for those with advanced or metastatic MM. Options includedacarbazine, temozolomide, IL-2, paclitaxel, cisplatin, carbo-
platin, IFN-α2b, and ipilimumab [15].
MM and CCSTA are very similar histologically, which
led Chung and Enzinger to propose “malignant melanoma
of soft parts” as a preferred name for clear cell sarcoma in
1983 [4]. The two are often difficult to differentiate be-
cause 70-90% of clear cell sarcomas express melanin due
to fusion of the EWS and ATF1 genes from chromosomes
22q12 and 12q13 respectively. Further complicating differ-
entiation between the two cancers is the fact that histo-
logical samples of both CCSTA and MM will stain
positively for S-100 and HMB-45 [2]. Proper identification
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oma stains, and via FISH to detect EWS gene rearrange-
ment [18]. Also, diagnosis of malignant melanoma can be
made if a BRAF mutation is found [14]. This case was par-
ticularly difficult to diagnose due to the lack of V600E
BRAF mutation and negative EWS rearrangement, either
of which could have greatly clarified the diagnosis.
Conclusions
While sometimes difficult to distinguish, clear cell
sarcoma can be differentiated from malignant mela-
noma by examining a combination of primary tumor
location, dissemination, growth speed, staining with
MART-1 and MITF, and FISH detection of EWS gene
rearrangement. This case presented a diagnostic chal-
lenge due to a number of factors: the patient fit the
epidemiology of CSSTA (younger adult, tumor of the
lower leg), the massive and hemorrhaging nature of
the leg tumor masked whether the tumor origin cells
came from the skin or soft tissue, and histologic
markers of CSSTA and MM are very similar.
In the end, definitive diagnosis was made due to the
fast-growing and widely disseminated nature of the cancer,
positive staining with MART-1 and MITF, and FISH ana-
lysis revealing normal EWS gene. Although the original
resection was performed before the definitive diagnosis
was made, the thorough analysis eventually led to the
proper diagnosis of MM, which allowed for treatment
with ipilimumab upon recurrence with good response.
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